NCT02509624View on ClinicalTrials.gov

Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Normal and Impaired Hepatic Function

PHASE1CompletedINTERVENTIONAL

Enrollment

52

Participants

Timeline

Start Date

August 18, 2015

Primary Completion Date

December 15, 2015

Study Completion Date

December 15, 2015

Conditions

Diabetic Kidney Disease

Interventions

DRUG

Selonsertib

6 mg tablets administered orally in fed state

Trial Locations (5)

Unknown

Denver

Miami

Orlando

Minneapolis

San Antonio

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY